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Cardiac Anesthesia
Jodi S. Cain, BS, DVM*
Martha Buttrick, DVM**
Introduction
The purpose of general anesthesia is
to provide analgesia, unconsciousness, muscle
relaxation and suppression of autonomic and
somatic reflexes. 1 A patient with cardiac
disease may require general anesthesia for
angiography or angioplasty or for another
reason unrelated to the heart. Safe anesthesia
requires careful evaluation of the cardiopulmon-
ary systenl. A preanesthetic work up should
include a complete physical exam, blood work,
an electrocardiogram and thoracic radiographs.
The hemodynamic changes expected with heart
disease need to be reviewed along with the
effects of the cardiac drugs used to treat the
condition. The potential interaction of these
drugs with anesthetic agents also needs to be
considered. An arrhythmia needs to be
identified and treated before anesthesia. 1,2,3
These animals may be a challenge to anesthe-
tize.
Anesthesia for the Cardiac Patient
Before anesthetizing a cardiac patient,
it is imperative that the anesthesiologist
understand how the anesthetics work and the
physiologic changes they cause. Many of these
animals will have altered distribution of drugs
due to decreased muscle mass and decreased
albumin levels. Pulmonary compliance can be
reduced due to chronically elevated pulmonary
capillary pressure. This may lead to ventilation/
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perfusion mismatches.3 Decreased myocardial
function can enhance the myocardial effects of
anesthesia. The decrease in renal blood flow
that accompanies general anesthesia, com-
pounded with cardiac insuf'ficiency, can cause a
slowed elimination of many drugs, thus it
increases the chance of overdosages.3
Anticholinergics (atropine, glycopyrro-
late) competitively antagonize postganglionic
parasympathetic cholinergic receptors. They
are primarily used in conjunction with general
anesthesia to prevent salivary secretions and to
treat bradycardia due to increased vagal
stimulation. Glycopyrrolate does not cross the
blood brain barrier and it has fewer cardiovas-
cular effects than atropine.1 Atropine can cause
drowsiness and potentiate eNS depressant
drugs' effects. Sinus tachycardia and first and
second degree AV block can be seen after
administration of either of these drugs.2 Their
routine use as a premedication should be
examined because anticholinergics increase
myocardial work, myocardial irritation and
myocardial oxygen demand. 1,5 The effects of
the phenothiazines (acepromazine and promaz-
ine) and the butyrophenones (droperidol,
lenperone, azaperone) are mediated by anti-
dopaminergic actions and by sympathetic
nervous system suppression. The phenothiazi-
nes also decrease the seizure threshold. They
cause a calming effect but lack analgesic
properties. These drugs cause blockade of the
sympathetic alpha-adrenergic receptors which
causes hypotension with reflex tachycardia. 1
Myocardial contractility is also depressed.
Sensitivity to epinephrine-induced arrhythmias
is decreased by their administration.5,6 In low
doses, they are considered a good premedica-
tion choice for patients with mitral insufficiency,
as they reduce afterload.3
Benzodiazepines (diazepam and
midazolam) enhance the activity of the central
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nervous system inhibitory neurotransmitters
(GABA, glycine) and conlbine with benzodiaz-
epine receptors in the CNS. These drugs are
not used alone as premedications because they
produce unreliable effects. Muscle relaxation
occurs because of decreased polysynaptic
reflex activity. They also have an anticonvul-
sant effect. Cardiac side effects of diazepam's
propylene glycol carrier are seen with rapid
intravenous administration.4These effects are
hypotension, bradycardia, cardiac arrhythmias
and apnea. When given slowly these agents
have negligible depressant effects.3 Midazolam
works well when conlbined with ketamine or
oxynl0rphone.4
Xylazine blocks the action of the
alpha-2 adrenergic receptors, decreasing the
release of norepinephrine. Its actions can be
reversed by the administration of yohimbine.
This drug should be avoided in cardiac patients
due to its cardiopulnlonary depressant ef-
fects.1,5,7 Initially it causes a transient blood
pressure increase, but this is followed by a fall
in blood pressure. It causes a bradycardia
(parasympathetic activity) and it increases
cardiac sensitivity to catecholamine induced
arrhythnlias. Overall, the cardiac output may
decrease by as much as 33% due to an
increase in peripheral resistance and bradycar-
dia.5,7 Administration of glycopyrrolate along
with xylazine to counteract the bradycardia
does not alleviate the decreased cardiac
performance, but in fact worsens it.8
Synthetic opioids reversibly conlbine
with specific opiate and nonopiate receptors in
the CNS. This class of drugs includes mor-
phine, oxymorphone, meperidine and fentanyl.
Butorphanol and pentozocaine have synthetic
opioid agonist-antagonist effects.9 These
drugs cause a dose dependent respiratory
depression and a bradycardia due to stimula-
tion of medullary vagal nuclei, and are a good
choice for a preanesthetic medication as they
have little effect on the myocardium.5 Their
respiratory depressive effect must be consid-
ered when premedicating an animal with
pulmonary dysfunction. 1O ,11
Ultrashort acting barbiturates (thiamy-
lal, thiopental, methohexital) can be used as
induction agents. Their mechanism of action is
not completely understood, but they cause CNS
depression. Cardiac arrhythmias and myocar-
dial depression are seen when the barbiturate
is given as a bolus or in large doses. They also
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cause brief periods of apnea after administra-
tion. The cardiac arrhythmias and myocardial
depression seen when thiopental is used alone
can be decreased by concurrent adnlinistration
of lidocaine. This is done by starting with the
barbiturate and alternating its injection with
lidocaine in increments of 4.4 mg/kg until a total
dose of 8.8 mg/kg of each drug has been
injected intravenously. Do not mix these drugs
in the same syringe as an insoluble precipitate
will form. This combination has been shown to
lower the occurrence of the thiopental-induced
arrhythmias by decreasing the amount of the
thiopental required and by decreasing the sen-
sitivity of the myocardium to catecholamine-
induced arrhythmias.12
The dissociative anesthetic agents
include ketanline, phencyclidine and tiletamine.
The adminstration of these drugs can cause
irregular, apneustic and shallow breathing. An
incieased heart rate, increased blood pressure
and increased cardiac contractility may occur in
healthy patients. Ketamine should be used with
caution in patients with a diseased myocardium
or valvular insufficiency. It has been shown that
its direct effect on the heart is to decrease the
contractility of the myocardium. This combined
with the fact that it increases the pulmonary
vascular resistance, pulmonary arterial and
capillary wedge pressure, mean arterial
pressure and central venous pressure means
that ketamine actually increases the workload
on a diseased heart. This effect has been
demonstrated in patients who have little cardiac
reserve and a sympathetic system with limited
ability to override the direct depressant effect. 13
Ketamine also has an antiarrhythmic effect on
the heart. 13 It is not used alone because of its
potential to cause seizures in dogs. Ketamine
may be used in combination with other drugs
(I.e. midazolam, diazepam, or oxymorphone) to
minimize its undesirable effects.5 And when
used this way is a good induction choice for
cardiac patients. The combination of tiletamine-
zolazepam has similar effects on the cardiovas-
cular system as the ketamine-diazepam
combination (heart rate and blood pressure
increase).14
Mask inhalation induction with
isoflurane or halothane should also be consid-
ered for these compromised patients, but stress
and excitement must be kept to a minimum.22
The patients should receive preoxygenation
prior to induction and should be handled gently
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in order to reduce stress and struggling.1 An
inhalant gas' ability to produce anesthesia is
dependent on alveolar ventilation, blood/gas
partition coefficient, cardiac output, and alveolar
to mixed venous anesthetic partial pressure
difference, thus a left-right cardiac shunt or
ventilation/perfusion mismatches will slow the
rate of anesthetic induction.5
Halothane causes direct depth-related
vascular smooth muscle depression and
vasodilation which leads to hypotension.5,13 It
also directly depresses the myocardium,15
decreases sympathetic tone, causing bradycar-
dia at deep planes of anesthesia, and very
importantly, it sensitizes the heart to catechol-
amine-induced arrhythnlias.6
Methoxy'flurane's cardiac depression is
similar to halothane's except that sensitization
to catecholamine-induced arrhythmias is
lessened.5,16 Methoxyflurane would not be a
good choice for mask induction because
induction time is long.5
Isoflurane causes minimal cardiac
depression when compared to the other two
inhalants. It still slightly decreases the contrac-
tility, but the cardiac output is better maintained
at anesthetic levels. It does not sensitize the
heart to arrhythmias. Isoflurane is the best
inhalant choice for a cardiac patient as it allows
rapid and precise regulation of anesthetic
length and depth.3
Nitrous oxide has very few detrimental
cardiovascular effects.5 When used in combi-
nation with another inhalant at 50°10 N20/5001o
02 it will decrease the minimum alveolar
concentration by 20-50°10.5 ,16 The use of nitrous
oxide in cardiac patients must be considered
carefully, especially in an animal 'Nith pleural
effusion or pulmonary edema due to congestive
heart failure. The use of nitrous oxide will not
only decrease the dose of the anesthetic gas,
but it will decrease the oxygen concentration of
the inspired air.3
A balanced anesthetic protocol is
probably the best choice for these patients. An
example protocol is oxymorphone and/or
fentanyl, low-dose isoflurane, oxygen plus
nitrous oxide, and possibly atracurium (neuro-
muscular blocker). By combining these drugs a
smaller dosage of each is used, thus decreas-
ing the adverse side effects seen when each is
used separately.
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Monitoring
It is imperative that cardiac patients be
monitored closely. Their parameters change
rapidly and close observation is the only way to
catch a significant change before it becomes
critical. In addition to monitoring respiration and
heart rate, other parameters such as blood
pressure, central venous pressure, urinary
output, ventilation, core body temperature, and
arterial and venous blood gases should be
monitored.1
Direct blood pressure monitoring
provides information about organ perfusion.
Capillary refill time and mucous membrane
color correspond roughly to capillary perfusion.
If a blood pressure monitor is not available,
measuring urine output will give some idea of
renal perfusion and therefore systemic blood
pressure. If mean systemic arterial pressure is
<60 mm Hg, urine output will be < 1.0ml/kg/
hr.1,5 Anuria can occur with normal blood
pressure so urine monitoring alone may not
always be a truly accurate indication of blood
pressure.
The compromised heart can not adjust
to hypoxemia. Pa02< 60 mmHg causes an
increased cardiac work load and thus oxygen
demand is increased. Postoperative shivering
causes an increase in whole body oxygen
usage, thus hypothermia should be avoided.
Pulmonary ventilation monitoring via blood
gases or a respirometer is a good idea.1
Cardiac depression occurs at pH <
7.2, as intracellular acidosis inhibits binding of
calcium, decreasing myocardial contractile
strength. 1O Venoconstriction can also result
from acidemia, which in turn can cause cardiac
overload with the diseased heart. Alkalosis
causes increased myocardial work and oxygen
demand. Blood gas analysis will aid in monitor-
ing the acid-base balance of the patient.
Monitoring of an ECG prior to and during
anesthesia to detect arrhythmias is important.
If an arrhythmia is present, it should be treated
as soon as possible to improve cardiac output. 10
Fluid administration should be
monitored carefully to avoid excessive fluids
that may increase the cardiac workload. Too
few fluids can reduce preload and also cause
inadequate volume, resulting in decreased
systemic perfusion. Significant blood loss
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should be replaced to avoid loss of oxygen
carrying capacity and reduced systemic organ
perfusion. 1 The type of fluid administered
needs care'fu I consideration. If the patient has
a history of congestive heart failure or the
possibility is good that it may develop (i.e.
enlarged heart on radiographs) the use of a
fluid without sodium is advisable. Five percent
dextrose in water is a good choice.
Summary
Anesthesia can be performed safely
on the cardiac compromised patient with proper
consideration of the disease pathophysiology
and the cardiac and anesthetic drugs being
used. Monitoring need not be extensive but it
should be complete. An example that all small
animal practitioners will encounter is the old
dog with mild to moderate mitral insufficiency
that requires a dental.
First, the physical exam and history
must be complete. The cardiac drugs the dog
is receiving need to be reviewed along with the
pathophysiology of the disease.
Next, a safe anesthetic protocol rnust
be decided on depending on the results of the
physical and diag~ostic work-up (CBC, serum
chemistries, ECG and chest radiographs). If
the dog is easily excited, a light premedication
with a synthetic opioid should be administered.
If the dog is calm enough to mask induce
without premedication this can also be consid-
ered.
Induction choices include thiopental/
lidocaine, synthetic opioids, rnidazolam/
ketarnine or nlask induction with preferably
isoflurane. If possible, it is ideal to preoxyge-
nate this animal especially if there is respiratory
dysfunction.
The use of isoflurane or isoflurane/
NO/02 is the preferred method for maintaining
these animals. Halothane combined with NO)
02 could be used if isoflurane is unavailable.
These patients must have closer
monitoring than the normal healthy animal. The
monitoring need not be invasive but it should be
as complete as possible. The heart rate and
respiration should be noted. A blood pressure
monitor would be ideal but a combination of
pulse pressure, mucous membrane color and
capillary refill time would suffice. ECG monitor-
ing beginning at induction should also be
included. The aninlal's body temperature
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needs to be maintained as close to normal as
possible.
Fluids for an animal with congestive
heart failure or the potential of should be 5%
dextrose/water (avoid fluids containing sodium).
If there is no radiographic heart abnormality and
no clinical signs of heart failure then the usage
of lactated Ringer's would be adequate. The
fluids need to be carefully monitored to avoid
administering too much or too little.
All currently prescribed cardiac
medications should be continued at their
indicated dosages and dosing intervals during
the anesthetic episode.
There is nothing extremely compli-
cated to anesthetizing the cardiac patient. If the
work-up and physical exam are complete and
the disease and drugs have been reviewed, an
anesthetic protocol can easily be decided upon
and followed.
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